Skip to main content
Top
Published in: Calcified Tissue International 1/2003

01-07-2003 | Clinical Investigations

Urinary Excretion of Pyridinium Cross-Links and Serum Osteocalcin Levels in Patients with Primary High-Grade Osteosarcoma

Authors: S. Ferrari, C. Zolezzi, L. Pratelli, M. C. Fasano, G. Bacci

Published in: Calcified Tissue International | Issue 1/2003

Login to get access

Abstract

Osteosarcoma is the most frequent primary high grade bone tumor, usually occurring in adolescents and children. The aim of the present study was to investigate parameters of bone turnover as urinary excretion of pyridinoline (Pyr), and deoxypyridinoline (D-Pyr), serum osteocalcin (OC), and total alkaline phosphatase (AP) in patients with osteosarcoma. Thirty-five patients aged 7–22 (median age 14) with primary high-grade osteosarcoma of the extremity entered the study. A control population of age- and sex-matched healthy individuals was studied. Urinary excretion of Pyr, D-Pyr was measured on fasting urine specimens, corrected for creatine excretion (Ucr), and expressed as pM/µM UCr. At the same time as urine collection, blood samples were taken for measurement of AP and OC. In patients with osteosarcoma the urinary excretion of D-Pyr (74.5 ± 41) was significantly higher (P = 0.005) than in controls (38.2 ± 22.5). The serum level of OC was significantly lower (P < 0.001) in patients with osteosarcoma than in controls. Moreover, significantly (P = 0.03) higher excretion of D-Pyr (85.3 ± 43) was found in patients who relapsed after surgical removal of the tumor and chemotherapeutic treatment compared with those (58.1 ± 22) who remained continuously free of disease. The present study showed significant abnormalities of urinary excretion of pyridinium crosslinks and serum OC level in patients with osteosarcoma. The relation between urinary excretion of D-Pyr and biological tumor aggressiveness observed in the present study requires further investigation.
Literature
1.
go back to reference Campanacci, M 1999High grade osteosarcomas.Campanacci, M eds. Bone and soft tissue tumors.Springer-VerlagWien-New York463 Campanacci, M 1999High grade osteosarcomas.Campanacci, M eds. Bone and soft tissue tumors.Springer-VerlagWien-New York463
2.
go back to reference Kanis, JA, McCloskey, EV 1997Bone turnover and biochemical markers in malignancy.Cancer8015381545CrossRefPubMed Kanis, JA, McCloskey, EV 1997Bone turnover and biochemical markers in malignancy.Cancer8015381545CrossRefPubMed
3.
go back to reference Demers, LM, Costa, L, Chinchilli, VM, Gaydos, L, Curley, E, Lipton, A 1995Biochemical markers of bone turnover in patients with metastatic bone disease.Clin Chem4114891494PubMed Demers, LM, Costa, L, Chinchilli, VM, Gaydos, L, Curley, E, Lipton, A 1995Biochemical markers of bone turnover in patients with metastatic bone disease.Clin Chem4114891494PubMed
4.
go back to reference Seibel, MJ, Duncan, A, Robins, SP 1989Urinary hydroxy-pyridinium crosslinks provide indices of cartilage and bone involvement in arthritic diseases.J Rheumatol16964970PubMed Seibel, MJ, Duncan, A, Robins, SP 1989Urinary hydroxy-pyridinium crosslinks provide indices of cartilage and bone involvement in arthritic diseases.J Rheumatol16964970PubMed
5.
go back to reference Delmas, PD, Schlemmer, A, Gineyts, E, Riis, B, Christiansen, C 1991Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis.J Bone Miner Res6639644PubMed Delmas, PD, Schlemmer, A, Gineyts, E, Riis, B, Christiansen, C 1991Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis.J Bone Miner Res6639644PubMed
6.
go back to reference Brown, JP, Delmas, PD, Malaval, L, Edouard, C, Chapuy, MC, Meunier, PJM 1984Serum bone Gla protein: a specific marker for bone formation in postmenopausal osteoporosis.LancetI10911093CrossRef Brown, JP, Delmas, PD, Malaval, L, Edouard, C, Chapuy, MC, Meunier, PJM 1984Serum bone Gla protein: a specific marker for bone formation in postmenopausal osteoporosis.LancetI10911093CrossRef
7.
go back to reference Gobel, V, Jurgens, H, Etspuler, G 1987Prognostic significance of tumor volume in localized Ewing’s sarcoma of bone in children and adolescents.J Cancer Res Clin Oncol113187191PubMed Gobel, V, Jurgens, H, Etspuler, G 1987Prognostic significance of tumor volume in localized Ewing’s sarcoma of bone in children and adolescents.J Cancer Res Clin Oncol113187191PubMed
8.
go back to reference Uebelhart, D, Gineyts, E, Chapuy, MC, Delmas, PD 1990Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease.Bone Miner88796PubMed Uebelhart, D, Gineyts, E, Chapuy, MC, Delmas, PD 1990Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease.Bone Miner88796PubMed
9.
go back to reference Berruti, A, Dogliotti, L, Gorzegno, G, Torta, M, Tampellini, M, Tucci, M, Cerutti, S, Mosca Frezet, M, Stivanello, M, Sacchetto, G, Angeli, A 1999Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases.Clin Chem4512401247PubMed Berruti, A, Dogliotti, L, Gorzegno, G, Torta, M, Tampellini, M, Tucci, M, Cerutti, S, Mosca Frezet, M, Stivanello, M, Sacchetto, G, Angeli, A 1999Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases.Clin Chem4512401247PubMed
10.
go back to reference Meyers, PA, Heller, G, Healey, J, Huvos, A, Lane, J, Marcove, R, Applewhite, A, Vlamis, V, Rosen, G 1992Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience.J Clin Oncol10515PubMed Meyers, PA, Heller, G, Healey, J, Huvos, A, Lane, J, Marcove, R, Applewhite, A, Vlamis, V, Rosen, G 1992Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience.J Clin Oncol10515PubMed
11.
go back to reference Ferrari, S, Bertoni, F, Mercuri, M, Picci, P, Giacomini, S, Longhi, A, Bacci, G 2001Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute.Ann Oncol1211451150CrossRefPubMed Ferrari, S, Bertoni, F, Mercuri, M, Picci, P, Giacomini, S, Longhi, A, Bacci, G 2001Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute.Ann Oncol1211451150CrossRefPubMed
12.
go back to reference Arikoski, P, Komulainen, J, Riikonen, P, Voutilainen, R, Knip, M, Kroger, H 1999Alterations in bone turnover and impaired development of bone mineral density in newly diagnosed children with cancer: a 1-year prospective study.J Clin Endocrinol Metab8431743181PubMed Arikoski, P, Komulainen, J, Riikonen, P, Voutilainen, R, Knip, M, Kroger, H 1999Alterations in bone turnover and impaired development of bone mineral density in newly diagnosed children with cancer: a 1-year prospective study.J Clin Endocrinol Metab8431743181PubMed
13.
go back to reference Koizumi, M, Maeda, H, Yoshimura, K, Yamauchi, T, Kawai, T, Ogata, E 1997Dissociation of bone formation markers in bone metastasis of prostate cancer.Br J Cancer7516011604PubMed Koizumi, M, Maeda, H, Yoshimura, K, Yamauchi, T, Kawai, T, Ogata, E 1997Dissociation of bone formation markers in bone metastasis of prostate cancer.Br J Cancer7516011604PubMed
14.
go back to reference Hopyan, S, Gokgoz, N, Bell, RS, Andrulis, IL, Alman, BA, Wunder, JS 1999Expression of osteocalcin and its transcriptional regulators core-binding factor alpha 1 and MSX2 in osteoid-forming tumours.J Orthop Res17633638PubMed Hopyan, S, Gokgoz, N, Bell, RS, Andrulis, IL, Alman, BA, Wunder, JS 1999Expression of osteocalcin and its transcriptional regulators core-binding factor alpha 1 and MSX2 in osteoid-forming tumours.J Orthop Res17633638PubMed
Metadata
Title
Urinary Excretion of Pyridinium Cross-Links and Serum Osteocalcin Levels in Patients with Primary High-Grade Osteosarcoma
Authors
S. Ferrari
C. Zolezzi
L. Pratelli
M. C. Fasano
G. Bacci
Publication date
01-07-2003
Publisher
Springer-Verlag
Published in
Calcified Tissue International / Issue 1/2003
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-002-1046-1

Other articles of this Issue 1/2003

Calcified Tissue International 1/2003 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.